EntreMed Shows Increased Survival In Preclinical Renal Cell Cancer Model
EntreMed presented results for its cell cycle inhibitor, MKC-1, in preclinical cancer renal cell carcinoma (RCC) models.
This entry was posted
on Saturday, October 27th, 2007 at 1:00 am and is filed under General.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.